Correlation Between Viridian Therapeutics and Novo Nordisk

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Viridian Therapeutics and Novo Nordisk at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Viridian Therapeutics and Novo Nordisk into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Viridian Therapeutics and Novo Nordisk AS, you can compare the effects of market volatilities on Viridian Therapeutics and Novo Nordisk and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Viridian Therapeutics with a short position of Novo Nordisk. Check out your portfolio center. Please also check ongoing floating volatility patterns of Viridian Therapeutics and Novo Nordisk.

Diversification Opportunities for Viridian Therapeutics and Novo Nordisk

0.06
  Correlation Coefficient

Significant diversification

The 3 months correlation between Viridian and Novo is 0.06. Overlapping area represents the amount of risk that can be diversified away by holding Viridian Therapeutics and Novo Nordisk AS in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Novo Nordisk AS and Viridian Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Viridian Therapeutics are associated (or correlated) with Novo Nordisk. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Novo Nordisk AS has no effect on the direction of Viridian Therapeutics i.e., Viridian Therapeutics and Novo Nordisk go up and down completely randomly.

Pair Corralation between Viridian Therapeutics and Novo Nordisk

Given the investment horizon of 90 days Viridian Therapeutics is expected to under-perform the Novo Nordisk. In addition to that, Viridian Therapeutics is 1.07 times more volatile than Novo Nordisk AS. It trades about -0.13 of its total potential returns per unit of risk. Novo Nordisk AS is currently generating about -0.11 per unit of volatility. If you would invest  8,605  in Novo Nordisk AS on December 29, 2024 and sell it today you would lose (1,725) from holding Novo Nordisk AS or give up 20.05% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Viridian Therapeutics  vs.  Novo Nordisk AS

 Performance 
       Timeline  
Viridian Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Viridian Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of conflicting performance in the last few months, the Stock's fundamental indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.
Novo Nordisk AS 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Novo Nordisk AS has generated negative risk-adjusted returns adding no value to investors with long positions. Despite conflicting performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders.

Viridian Therapeutics and Novo Nordisk Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Viridian Therapeutics and Novo Nordisk

The main advantage of trading using opposite Viridian Therapeutics and Novo Nordisk positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Viridian Therapeutics position performs unexpectedly, Novo Nordisk can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novo Nordisk will offset losses from the drop in Novo Nordisk's long position.
The idea behind Viridian Therapeutics and Novo Nordisk AS pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.

Other Complementary Tools

Fundamental Analysis
View fundamental data based on most recent published financial statements
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency